Targeting a key protein that helps aggressive prostate cancer spread
Mechanisms and therapeutic targeting of lethal prostate cancer master regulator transcription factors
Researchers are testing ways to block the GATA2 protein to help men with advanced, treatment-resistant prostate cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Mayo Clinic Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project ID | NIH-11262847 on NIH RePORTER |
What this research studies
This project focuses on GATA2, a master regulatory protein that becomes more active in advanced prostate cancer and helps cancer cells change their behavior. Researchers will use tumor samples, single-cell RNA sequencing, computer analyses, and laboratory experiments to map how GATA2 alters cancer cells and which genes it controls. They will test approaches to block GATA2-driven programs in cell and animal models and look for strategies that reduce invasiveness or restore sensitivity to current treatments. The work aims to point toward medicines and biomarkers that could guide care for men with aggressive prostate cancer.
Who could benefit from this research
Good fit: Men with advanced or metastatic prostate cancer, especially those whose disease no longer responds to standard therapies, would be the most likely candidates for related future trials or sample donation.
Not a fit: Patients with early-stage, localized prostate cancer or tumors that do not rely on GATA2-driven biology are unlikely to benefit directly from this research.
Why it matters
Potential benefit: If successful, this work could lead to new treatments that slow or stop the spread of advanced prostate cancer and help existing therapies work better.
How similar studies have performed: Laboratory studies support GATA2's role in aggressive prostate cancer, but directly targeting this kind of master regulator is a relatively new and unproven approach in patients.
Where this research is happening
Rochester, United States
- Mayo Clinic Rochester — Rochester, United States (Active)
Researchers
- Principal investigator: Domingo-Domenech, Josep Maria — Mayo Clinic Rochester
- Study coordinator: Domingo-Domenech, Josep Maria
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.